TACOTINIB ER 11

Tofacitinib extended release 11 mg is a prescription medicine containing tofacitinib, a Janus kinase (JAK) inhibitor used for certain inflammatory and immune-mediated conditions. The extended-release (XR) formulation is designed for once-daily administration in approved adult indications such as moderately to severely active rheumatoid arthritis and active psoriatic arthritis. Depending on the country's approved labeling, tofacitinib may also be used for other conditions, including ulcerative colitis and ankylosing spondylitis.

If you are looking to buy Tofacitinib Extended Release 11 mg, understanding its approved uses, benefits, dosage instructions, side effects, drug interactions, and safety warnings is essential. This is not a routine painkiller or nutritional supplement. Tofacitinib affects the immune system and should be taken only under appropriate medical supervision.

What Is Tofacitinib Extended Release 11 mg?

Tofacitinib Extended Release 11 mg is an extended-release oral formulation of tofacitinib. In the U.S. XELJANZ XR labeling, the 11 mg extended-release tablet is a once-daily formulation used for certain adult inflammatory diseases. The prescribing information specifically states that XELJANZ XR 11 mg once daily corresponds to tofacitinib 5 mg twice daily for approved adult rheumatoid arthritis and psoriatic arthritis dosing.

The extended-release formulation should not be treated as automatically interchangeable with immediate-release tofacitinib. Current prescribing information states that switching between formulations should be directed by a healthcare professional.

Different manufacturers may sell tofacitinib 11 mg extended-release tablets under different brand names. Before purchasing, always verify the active ingredient, strength, dosage form, manufacturer, and prescription requirements on the product packaging.

Tofacitinib Extended Release 11 mg: Uses

The primary uses of Tofacitinib Extended Release 11 mg are related to certain moderate-to-severe inflammatory and immune-mediated diseases.

Depending on the local approved product information, tofacitinib may be prescribed for the following:

• Moderately to severely active rheumatoid arthritis

• Active psoriatic arthritis

• Ankylosing spondylitis in jurisdictions where approved

• Ulcerative colitis, under the specific dosing regimen approved for the patient and formulation

Current Indian pharmacy listings for tofacitinib 11 mg XR products commonly describe use for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.

However, the exact indication depends on the specific product and regulatory approval in your country. Do not self-diagnose or begin treatment based solely on an online product description.

How Does Tofacitinib Work?

Tofacitinib belongs to a class of medicines known as JAK inhibitors. Janus kinases are enzymes involved in signaling pathways used by various inflammatory and immune responses.

By inhibiting JAK activity, tofacitinib can reduce signaling involved in inflammation and immune-system activity. This can help control symptoms and disease activity in certain inflammatory conditions.

Because the medicine modifies immune-system activity, its benefits must be balanced against important risks, including serious infections and other potentially serious adverse events. The official prescribing information carries a boxed warning concerning serious infections, mortality, malignancy, major cardiovascular events, and thrombosis.

Key Benefits of Tofacitinib Extended Release 11 mg

1. Helps Control Inflammatory Disease Activity

Tofacitinib can reduce abnormal inflammatory signaling in conditions for which it is approved. In rheumatoid arthritis and psoriatic arthritis, this can help reduce disease activity and associated symptoms.

2. May Reduce Joint Symptoms

In inflammatory arthritis, controlling the underlying inflammatory process may reduce symptoms such as joint pain, swelling, tenderness, and stiffness. Current product information describes tofacitinib 11 mg XR products as helping decrease pain, tenderness, and joint swelling.

3. Once-Daily Extended-Release Formulation

One practical benefit of the XR formulation is its once-daily dosing for certain approved adult indications. The current Pfizer prescribing information lists XELJANZ XR 11 mg once daily for rheumatoid arthritis and psoriatic arthritis.

4. Oral Treatment Option

Tofacitinib is taken orally, providing an alternative to injectable therapies for patients who are appropriate candidates for JAK-inhibitor treatment.

Tofacitinib Extended Release 11 mg Dosage

Do not determine your dose from the strength printed on an online product listing. The correct dose depends on the condition being treated, kidney and liver function, other medicines, and the exact formulation.

For example, current U.S. labeling lists XELJANZ XR 11 mg once daily for adult rheumatoid arthritis and psoriatic arthritis. The same labeling uses different dosing for ulcerative colitis, including higher-dose induction with the appropriate formulation before maintenance treatment.

Patients with moderate or severe renal impairment or moderate hepatic impairment may require a different regimen; the prescribing information specifies dose adjustments for these situations.

Take the medicine exactly as prescribed. Do not increase, decrease, crush, or change the formulation unless your doctor or pharmacist instructs you to do so.

How to Take Tofacitinib Extended Release 11 mg

Follow your prescription and the instructions supplied with your particular product.

Current product information indicates that tofacitinib XR tablets can generally be taken with or without food and should be taken at approximately the same time each day.

Because this is an extended-release formulation, do not assume that it can be substituted tablet-for-tablet with immediate-release tofacitinib. The official prescribing information specifically warns that the XR formulation is not interchangeable without appropriate healthcare-provider direction.

Tofacitinib Extended Release 11 mg Side Effects

Like other medicines that affect the immune system, tofacitinib can cause side effects.

Potential adverse effects include the following:

• Headache

• Upper respiratory tract infections

• Diarrhoea

• Nasopharyngitis

• Increased cholesterol levels

• Increased risk of infections

• Changes in blood counts

• Liver enzyme abnormalities

The severity and frequency of adverse effects vary among patients and indications.

More importantly, tofacitinib carries serious safety warnings. The official prescribing information warns about serious infections, mortality, malignancies, major adverse cardiovascular events, and thrombosis. Serious bacterial, fungal, viral, and opportunistic infections—including tuberculosis—have been reported.

Seek urgent medical attention if you develop symptoms such as severe breathing difficulty, chest pain, sudden weakness, severe infection symptoms, unexplained swelling or pain in a limb, or other potentially serious symptoms.

Important Safety Checks Before Starting Treatment

Doctors may perform several evaluations before starting tofacitinib.

Current prescribing information recommends considering:

• Active and latent tuberculosis evaluation

• Viral hepatitis screening

• Complete blood count

• Updating appropriate vaccinations

The U.S. labeling also provides laboratory thresholds under which treatment should not be initiated.

Tell your healthcare professional if you have a history of tuberculosis, recurrent infections, hepatitis, cancer, blood clots, heart disease, stroke, or other significant medical conditions.

Tofacitinib and Drug Interactions

Tofacitinib can interact with other medicines, particularly medicines that affect immune function or the enzymes responsible for drug metabolism.

Tell your doctor about all prescription medicines, over-the-counter medicines, supplements, and herbal products you take.

The official labeling states that use with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended for certain approved uses.

Never add another immunosuppressive medicine without medical supervision.

What to Check Before Buying Tofacitinib Extended Release 11 mg Online

If your intent is to buy Tofacitinib Extended Release 11 mg online, verify the following before purchasing:

1. Prescription requirement: Tofacitinib is a prescription medicine. Purchase and use should comply with local regulations.

2. Exact formulation: Confirm that the product says tofacitinib 11 mg extended-release/XR/ER, rather than immediate-release tofacitinib.

3. Manufacturer: Check the manufacturer's name and product registration information.

4. Packaging: Ensure the pack is sealed and displays batch, manufacturing, expiry, and composition information.

5. Seller authenticity: Use a legitimate pharmacy or authorized medicine supplier.

6. Price comparison: Compare the price per tablet and pack size rather than relying only on a percentage-discount claim.

Current Indian online pharmacy listings show multiple generic 11 mg extended-release tofacitinib products, with prices varying by manufacturer and pack size. For example, listings updated in August 2026 show products such as Tofza 11 mg Tablet XR, Tofaziff 11 XR, Tofe-ER, and Tofaton Tablet ER.

Frequently Asked Questions 

1. What is Tofacitinib Extended Release 11 mg used for?

Tofacitinib Extended Release 11 mg is used for certain inflammatory diseases, including moderately to severely active rheumatoid arthritis and active psoriatic arthritis. Depending on the country and product approval, tofacitinib may also be used for ankylosing spondylitis or ulcerative colitis.

2. Is Tofacitinib Extended Release 11 mg a steroid?

No. Tofacitinib is not a corticosteroid. It is a JAK inhibitor that modifies immune and inflammatory signaling.

3. What are the benefits of Tofacitinib 11 mg XR?

The medicine can help control inflammatory disease activity and may reduce symptoms such as joint pain, tenderness, swelling, and stiffness in appropriate patients. The XR formulation also offers once-daily administration for certain approved indications.

4. What are the common side effects of Tofacitinib Extended Release 11 mg?

Possible side effects include infections, headache, diarrhea, upper respiratory symptoms, increased cholesterol, blood-count changes, and liver enzyme abnormalities. Serious infections and other major risks are also included in the medicine's boxed warning.

5. Can Tofacitinib 11 mg XR be taken every day?

For certain approved adult conditions, the XR 11 mg formulation is prescribed once daily. However, the correct schedule depends on the diagnosis, formulation, kidney/liver function, and other medicines. Follow your doctor's prescription rather than choosing a schedule yourself.

6. Is Tofacitinib Extended Release 11 mg safe?

Tofacitinib can be effective when appropriately prescribed, but it has significant risks and requires medical monitoring. The official prescribing information warns about serious infections, malignancy, major cardiovascular events, thrombosis, and mortality.

7. Can I buy Tofacitinib Extended Release 11 mg without a prescription?

Tofacitinib is a prescription medicine in many markets. You should purchase it only through a legitimate pharmacy and use it under the supervision of an appropriate healthcare professional.

8. Can Tofacitinib 11 mg XR be substituted for Tofacitinib 5 mg twice daily?

For certain adult indications, the approved XR 11 mg once-daily regimen corresponds to 5 mg twice-daily immediate-release tofacitinib. This does not mean patients should switch formulations themselves. The official labeling says switching should be directed by a healthcare provider.

Conclusion

Tofacitinib extended release 11 mg is a prescription JAK inhibitor used for specific inflammatory and immune-mediated conditions. Its major advantages include targeted JAK-pathway inhibition, oral administration, and once-daily XR dosing for certain approved adult indications.

However, this is a medicine that requires substantially more caution than an ordinary painkiller or supplement. Serious infections, malignancies, cardiovascular events, blood clots, and other significant risks are included in the official safety warnings. Appropriate patients may also require screening and laboratory monitoring before and during treatment.